A ação anti-inflamatória do lítio é influenciada por fatores genéticos, nutricionais e fármacos antidepressivos: estudos in vitro

Detalhes bibliográficos
Ano de defesa: 2017
Autor(a) principal: Barbisan, Fernanda lattes
Orientador(a): Cruz, Ivana Beatrice Mânica da lattes
Banca de defesa: Pavanato, Maria Amália lattes, Bica, Claudia Giuliano lattes, Piccoli, Jacqueline da Costa Escobar lattes, Premaor, Melissa Orlandin lattes
Tipo de documento: Tese
Tipo de acesso: Acesso aberto
Idioma: por
Instituição de defesa: Universidade Federal de Santa Maria
Centro de Ciências da Saúde
Programa de Pós-Graduação: Programa de Pós-Graduação em Farmacologia
Departamento: Farmacologia
País: Brasil
Palavras-chave em Português:
Palavras-chave em Inglês:
Área do conhecimento CNPq:
Link de acesso: http://repositorio.ufsm.br/handle/1/13834
Resumo: Population aging has increased the prevalence of chronic non-communicable diseases, including psychiatric disorders such as depression and bipolar spectrum disorders (BSDs). Evidence suggests that such disorders are associated with chronic processes of inflammation and oxidative stress. Lithium is one of the main drugs of the psychiatric clinic, and its main mechanism of action is anti-inflammatory by inhibition of the enzyme GSK-3β. However, about 40% of patients do not respond satisfactorily to Lithium therapy. And, this absense of response may involve genetic polymorphisms, or even drug-food interaction, or drug-drug, since lithium is often associated with antidepressants or antipsychotics. Therefore, in this work we emphasize the action of the polymorphism Val16Ala-SOD2 which causes imbalance between the levels of Superoxide and Hydrogen Peroxide and is involved with oxidative and inflammatory metabolism. Bioactive molecules such as xanthines and catechins present in foods, which have an anti-inflammatory and antioxidant effect, and therefore, they could also influence the pharmacological response to lithium and the interaction lithium-antidepressants, often used in TEBs. To evaluate in vitro the influence of genetic and nutritional factors and pharmacological interaction with antidepressants on the anti-inflammatory response of lithium. Three experimental designs were conducted. The first work evaluated the influence of the anti-inflammatory response to the Lithium of peripheral blood mononuclear cells (PBMCs) through two complementary studies. Initially, a study was conducted to confirm that such genetic variation could cause a differentiated inflammatory response evaluating the immunosenescence profile of these cells. Therefore, PBMCs were obtained from volunteers with different Val16Ala-SOD2 genotypes and were cultured for 15 cell passages (60 days) under standardized conditions. At each passage the PBMCs were activated with phytohemagglutinin (PHA), an antigen that triggers inflammatory response. At each passage the PBMCs were activated with phytohemagglutinin (PHA), an antigen that triggers inflammatory response. Each passage was started at a concentration of 1 x 105 cells. The rate of cell proliferation at each passage was determined via MTT spectrophotometric assay and, eventually, by cell cycle analysis by flow cytometry. Pro-inflammatory markers and oxidative markers were also analyzed. We performed a second study, which evaluated the influence of the Val16Ala-SOD2 polymorphism on the modulation of the GSK-3β enzyme by Lithium through the analysis of the gene expression via qRT-PCR and the levels of protein via immunoassay ELISA. We also performed analyzes with the RAW 264.7 macrophages commercial lineage in order to confirm the results obtained in PBMCs. Supplementation of cultures with paraquat to generate VV-like cells (with high levels of superoxide) was used to simulate the S-HP imbalance And porphyrin generating AA-like cells (with elevated PH levels). The second protocol of this work evaluated the potential isolated effect and a mixture of the xanthines and catechins in the anti-inflammatory response of lithium in macrophages RAW 264.7, through the analysis of oxidative and inflammatory markers. Finally, the third protocol evaluated the effect of the interaction between Lithium, Imipramine, Nortriptyline, Fluoxetine and Escitalopram also using RAW 264.7 macrophages as an experimental model. In this latter protocol, an inflammatory index (II) was created in order to aggregate the results obtained. In order to validate the II, a similar analysis was performed to the cells in vitro, in a database of 154 volunteers. This additional analysis allowed to evaluate the accuracy of the II and its potential similarity with inflammatory situations that occur in vivo. In in vitro studies the results were compared by analysis of variance (one-way or two-way, as appropriate) followed by post hoc Dunnet, Tukey or Bonferroni, according to the case. In the in vivo study, a Roc curve was performed to assess whether IF was representative of an actual inflammatory condition. A pattern of immunosenescence was observed in all cultures up to the 15th passage, when there was an interruption in the cell cycle in the G0 / G1 phase. However, prior to that, from the 10th cell passage, there was a state of inflammatory hyperactivation with high rates of cell proliferation and increased levels of proinflammatory cytokines and oxidative markers. Despite this general pattern, AA PBMCs showed greater intensity in the initial inflammatory response, whereas VV PBMCs tended to maintain the inflammatory response longer. Therefore, the set of these results corroborated the suggestion that the S-PH imbalance has a direct influence on the modulation of inflammation. The second study of the first protocol observed that the S-PH imbalance, both genetically determined by the Val16Ala-SOD2 polymorphism and pharmacologically induced influenced the anti-inflammatory response of the Lithium-modulating GSK-3β enzyme. Imbalance induced a more intense anti-inflammatory effect of lithium on AA or AA-like cells. In the second protocol, which evaluated the effect of nutritional factors on the anti-inflammatory action of lithium, especially the mixture of xanthines-catechins intensified the anti-inflammatory response of Lithium via decrease in the levels of pro-inflammatory cytokines, increase in IL-10 levels and decrease in oxidative markers. Finally, the last protocol investigated the influence of the interaction between lithium and antidepressants. The II was validated via analysis of the ROC curve showed that the II is an accurate index in relation to the inflammation with an area on the curve (AUC) of 0.803 (95% confidence interval of 0.715-0.890). Values of II > 2.0 relative to Reactive Protein C levels> 0.6 μg / mL had a sensitivity of 0.915 and specificity of 0.486. Interaction with antidepressants has shown that when Lithium is associated with Imipramine, or Nortriptyline or Fluoxetine, there is an intensification of the anti-inflammatory effect, with a decrease in the II, However, the association with Escitalopram induces pro-inflammatory effects, with an increase in IF indicating the proinflammatory effect of this interaction. In summary, despite the methodological limitations related to the in vitro studies, the set of results confirmed that Lithium has an important anti-inflammatory effect, but that this effect is not universal since it can be influenced by genetic, nutritional factors and even by interaction with antidepressant drugs. These results may be relevant in the psychiatric clinic.
id UFSM_e363966bc66593f03dfe7a787966a348
oai_identifier_str oai:repositorio.ufsm.br:1/13834
network_acronym_str UFSM
network_name_str Biblioteca Digital de Teses e Dissertações do UFSM
repository_id_str
spelling 2018-07-18T14:05:44Z2018-07-18T14:05:44Z2017-09-01http://repositorio.ufsm.br/handle/1/13834Population aging has increased the prevalence of chronic non-communicable diseases, including psychiatric disorders such as depression and bipolar spectrum disorders (BSDs). Evidence suggests that such disorders are associated with chronic processes of inflammation and oxidative stress. Lithium is one of the main drugs of the psychiatric clinic, and its main mechanism of action is anti-inflammatory by inhibition of the enzyme GSK-3β. However, about 40% of patients do not respond satisfactorily to Lithium therapy. And, this absense of response may involve genetic polymorphisms, or even drug-food interaction, or drug-drug, since lithium is often associated with antidepressants or antipsychotics. Therefore, in this work we emphasize the action of the polymorphism Val16Ala-SOD2 which causes imbalance between the levels of Superoxide and Hydrogen Peroxide and is involved with oxidative and inflammatory metabolism. Bioactive molecules such as xanthines and catechins present in foods, which have an anti-inflammatory and antioxidant effect, and therefore, they could also influence the pharmacological response to lithium and the interaction lithium-antidepressants, often used in TEBs. To evaluate in vitro the influence of genetic and nutritional factors and pharmacological interaction with antidepressants on the anti-inflammatory response of lithium. Three experimental designs were conducted. The first work evaluated the influence of the anti-inflammatory response to the Lithium of peripheral blood mononuclear cells (PBMCs) through two complementary studies. Initially, a study was conducted to confirm that such genetic variation could cause a differentiated inflammatory response evaluating the immunosenescence profile of these cells. Therefore, PBMCs were obtained from volunteers with different Val16Ala-SOD2 genotypes and were cultured for 15 cell passages (60 days) under standardized conditions. At each passage the PBMCs were activated with phytohemagglutinin (PHA), an antigen that triggers inflammatory response. At each passage the PBMCs were activated with phytohemagglutinin (PHA), an antigen that triggers inflammatory response. Each passage was started at a concentration of 1 x 105 cells. The rate of cell proliferation at each passage was determined via MTT spectrophotometric assay and, eventually, by cell cycle analysis by flow cytometry. Pro-inflammatory markers and oxidative markers were also analyzed. We performed a second study, which evaluated the influence of the Val16Ala-SOD2 polymorphism on the modulation of the GSK-3β enzyme by Lithium through the analysis of the gene expression via qRT-PCR and the levels of protein via immunoassay ELISA. We also performed analyzes with the RAW 264.7 macrophages commercial lineage in order to confirm the results obtained in PBMCs. Supplementation of cultures with paraquat to generate VV-like cells (with high levels of superoxide) was used to simulate the S-HP imbalance And porphyrin generating AA-like cells (with elevated PH levels). The second protocol of this work evaluated the potential isolated effect and a mixture of the xanthines and catechins in the anti-inflammatory response of lithium in macrophages RAW 264.7, through the analysis of oxidative and inflammatory markers. Finally, the third protocol evaluated the effect of the interaction between Lithium, Imipramine, Nortriptyline, Fluoxetine and Escitalopram also using RAW 264.7 macrophages as an experimental model. In this latter protocol, an inflammatory index (II) was created in order to aggregate the results obtained. In order to validate the II, a similar analysis was performed to the cells in vitro, in a database of 154 volunteers. This additional analysis allowed to evaluate the accuracy of the II and its potential similarity with inflammatory situations that occur in vivo. In in vitro studies the results were compared by analysis of variance (one-way or two-way, as appropriate) followed by post hoc Dunnet, Tukey or Bonferroni, according to the case. In the in vivo study, a Roc curve was performed to assess whether IF was representative of an actual inflammatory condition. A pattern of immunosenescence was observed in all cultures up to the 15th passage, when there was an interruption in the cell cycle in the G0 / G1 phase. However, prior to that, from the 10th cell passage, there was a state of inflammatory hyperactivation with high rates of cell proliferation and increased levels of proinflammatory cytokines and oxidative markers. Despite this general pattern, AA PBMCs showed greater intensity in the initial inflammatory response, whereas VV PBMCs tended to maintain the inflammatory response longer. Therefore, the set of these results corroborated the suggestion that the S-PH imbalance has a direct influence on the modulation of inflammation. The second study of the first protocol observed that the S-PH imbalance, both genetically determined by the Val16Ala-SOD2 polymorphism and pharmacologically induced influenced the anti-inflammatory response of the Lithium-modulating GSK-3β enzyme. Imbalance induced a more intense anti-inflammatory effect of lithium on AA or AA-like cells. In the second protocol, which evaluated the effect of nutritional factors on the anti-inflammatory action of lithium, especially the mixture of xanthines-catechins intensified the anti-inflammatory response of Lithium via decrease in the levels of pro-inflammatory cytokines, increase in IL-10 levels and decrease in oxidative markers. Finally, the last protocol investigated the influence of the interaction between lithium and antidepressants. The II was validated via analysis of the ROC curve showed that the II is an accurate index in relation to the inflammation with an area on the curve (AUC) of 0.803 (95% confidence interval of 0.715-0.890). Values of II > 2.0 relative to Reactive Protein C levels> 0.6 μg / mL had a sensitivity of 0.915 and specificity of 0.486. Interaction with antidepressants has shown that when Lithium is associated with Imipramine, or Nortriptyline or Fluoxetine, there is an intensification of the anti-inflammatory effect, with a decrease in the II, However, the association with Escitalopram induces pro-inflammatory effects, with an increase in IF indicating the proinflammatory effect of this interaction. In summary, despite the methodological limitations related to the in vitro studies, the set of results confirmed that Lithium has an important anti-inflammatory effect, but that this effect is not universal since it can be influenced by genetic, nutritional factors and even by interaction with antidepressant drugs. These results may be relevant in the psychiatric clinic.O envelhecimento populacional aumentou a prevalência de doenças crônicas não-transmissíveis, incluíndo transtornos psiquiátricos como a depressão e transtornos do espectro bipolar (TEBs). Evidências sugerem que tais transtornos estão associadas a processos crônicos de inflamação e estresse oxidativo. O Lítio, é um dos principais fármacos da clínica psiquiátrica, e seu principal mecanismo de ação é anti-inflamatório por inibição da enzima GSK-3β. Entretanto, cerca de 40% dos pacientes não respondem a terapia com Lítio satisfatoriamente. E, essa falta de resposta pode envolver polimorfismos genéticos, ou ainda interação fármaco-alimento, ou fármaco-fármaco. Diante disso, nesse trabalho damos ênfase a ação do polimorfismo Val16Ala-SOD2 que causa desbalanço entre os níveis de Superóxido e peróxido de Hidrogênio e está envolvido com o metabolismo oxidativo e inflamatório. Moléculas bioativas como xantinas e catequinas presentes nos alimentos, que possuem efeito anti-inflamatório e antioxidante, e portanto, as mesmas também poderiam influenciar a resposta farmacológica ao lítio. E a interação lítio- antidepressivos, muitas vezes utilizada em TEBs. Assim, o objetivo desse estudo foi avaliar in vitro a influência de fatores genéticos, nutricionais e interação farmacológica com antidepressivos na resposta anti-inflamatória do lítio. Três delineamentos experimentais foram conduzidos. O primeiro trabalho avaliou que a influência da resposta anti-inflamatória ao Lítio de células mononucleares do sangue periférico (CMSPs) através de dois estudos complementares. Inicialmente foi conduzido um estudo que buscou confirmar que tal variação genética poderia causar resposta inflamatória diferenciada avaliando o perfil da imunosenescência destas células. Para tanto, CMSPs foram obtidas de voluntários com diferentes genótipos Val16Ala-SOD2 e foram cultivadas durante 15 passagens celulares (60 dias), em condições padronizadas. A cada passagem as CMSPs foram ativados com fitohemaglutinina (PHA), um antígeno que desencadeia resposta inflamatória. Cada passagem foi iniciada com uma concentração de 1 x 105 células. A taxa de proliferação celular a cada passagem foi determinada via ensaio espectrofotométrico do MTT e, eventualmente pela análise do ciclo celular por citometria de fluxo. Também foram analisados marcadores pró- inflamatórios e marcadores oxidativos. Realizamos um segundo estudo, que avaliou a influência do polimorfismo Val16Ala-SOD2 na modulação da enzima GSK-3β pelo Lítio através da análise da expressão gênica via qRT-PCR e dos níveis de proteína via imunoensaio ELISA. Também realizamos análises com a linhagem comercial de macrófagos RAW 264.7, a fim de confirmar os resultados obtidos em CMSPs. Para simular o desbalanço S-HP foi utilizado suplementação das culturas com paraquat gerando células VV-like (com níveis elevados de superóxido) e porfirina gerando células AA-like (com níveis elevados de PH). O segundo protocolo deste trabalho avaliou o potencial efeito isolado e de uma mistura das xantinas e catequina na resposta anti-inflamatória do lítio em macrófagos RAW 264.7, através da análise de marcadores oxidativos e inflamatórios. Por fim, o terceiro protocolo avaliou o efeito da interação entre o Lítio Imipramina, Nortriptilina, Fluoxetina e Escitalopram também utilizando macrófagos RAW 264.7 como modelo experimental. Neste último protocolo, foi criado um índice inflamatório (IF) a fim de agregar os resultados obtidos. A fim de validar o IF, foi conduzida uma análise similar às das células in vitro, em um banco de dados com 154 voluntários. Essa análise adicional permitiu avaliar a acurácia do IF e sua potencial similaridade com situações inflamatórias que ocorrem in vivo. Nos estudos in vitro os resultados foram comparados por análise de variância (de um a ou duas vias, conforme o caso) seguida de post hoc de Dunnet, Tukey ou Bonferroni, conforme o caso. No estudo in vivo foi realizada uma curva Roc a fim de avaliar se o IF era representativo de um estado inflamatório real. Um padrão de imunosenescência foi observado em todas as culturas até a 15ª passagem, quando ocorreu uma interrupção no ciclo celular na fase G0/G1. Entretanto, antes disso, a partir da 10ª passagem celular, ocorreu um estado de hiperativação inflamatória com altas taxas de proliferação celular e aumento nos níveis das citocinas pró-inflamatórias e dos marcadores oxidativos. Apesar deste padrão geral, CMSPs AA apresentaram maior intensidade na resposta inflamatória inicial, enquanto que CMSPs VV tenderam a manter por mais tempo a resposta inflamatória. Portanto, o conjunto destes resultados corroborou a sugestão de que o desbalanço S-PH tem influência direta na modulação da inflamação. O segundo estudo do primeiro protocolo observou que, o desbalanço S-PH, tanto geneticamente determinado pelo polimorfismo Val16Ala-SOD2 quanto farmacologicamente induzido influenciou a resposta anti-inflamatória do Lítio via modulação da enzima GSK-3β. O desbalanço induziu um efeito anti-inflamatorio mais intenso do lítio em células AA ou AA-like. No segundo protocolo, que avaliou o efeito de fatores nutricionais na ação anti-inflamatória do Lítio, especialmente a mistura de xantinas-catequina intensificou a resposta anti-inflamatória do Lítio via diminuição nos níveis das citocinas pró-inflamatórias, aumento nos níveis da IL-10 e diminuição de marcadores oxidativos. Por fim, o último protocolo investigou a influência da interação entre o Lítio e os antidepressivos. O IF foi validado via análise da curva ROC mostrou que o IF é um índice acurado em relação a inflamação com uma área sobre a curva (AUC) de 0,803 (intervalo de confiança a 95% de 0.715-0,890). Valores do IF > 2,0 em relação a níveis de Proteína C Reativa > 0.6 μg/mL apresentaram uma sensibilidade de 0,915 e especificidade de 0,486. Já a interação com antidepressivos, mostrou que quando o Lítio está associado a Imipramina, ou Nortriptilina ou Fluoxetina, ocorre uma intensificação do efeito anti-inflamação, com uma diminuição do IF, entretanto a associação com o Escitalopram induz a efeitos pró-inflamatórios, com um aumento no IF indicando efeito pró-inflamatório desta interação. Em síntese, apesar das limitações metodológicas relacionadas aos estudos in vitro, o conjunto dos resultados confirmou que o Lítio possui efeito anti-inflamatório importante, mas que este efeito não é universal, uma vez que ela pode ser influenciado por fatores genéticos, nutricionais e mesmo pela interação com fármacos antidepressivos. Esses resultados podem ser relevantes na clínica psiquiátrica.Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPESporUniversidade Federal de Santa MariaCentro de Ciências da SaúdePrograma de Pós-Graduação em FarmacologiaUFSMBrasilFarmacologiaAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessPolimorfismo genéticoImunosenescênciaXantinasCatequinasInflamaçãoEstresse oxidativoDepressãoTrantornos do espectro bipolarGenetic polymorphismImmunosenescenceXanthinesCatechinsInflammationOxidative stressDepressionBipolar disordersCNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIAA ação anti-inflamatória do lítio é influenciada por fatores genéticos, nutricionais e fármacos antidepressivos: estudos in vitroAntiinflammatory action of lithium is influenced by genetic, nutritional and antidepressant drugs: in vitro studiesinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesisCruz, Ivana Beatrice Mânica dahttp://lattes.cnpq.br/3426369324110716Pavanato, Maria Amáliahttp://lattes.cnpq.br/8701892865724171Bica, Claudia Giulianohttp://lattes.cnpq.br/4488122519766245Piccoli, Jacqueline da Costa Escobarhttp://lattes.cnpq.br/5099227329574183Premaor, Melissa Orlandinhttp://lattes.cnpq.br/1919693261808995http://lattes.cnpq.br/1428674947616182Barbisan, Fernanda2010000000006005000b5fcfe0-b017-4163-80e2-17c110fbcf0162685ca4-85d0-44a7-80c0-58948463d7b9ffd04c36-7494-45de-941b-897fca290f06b013a08e-c6c6-4bbd-b823-a19a27e3c61c1789009f-204a-4875-8758-7c9510ae4737e4bbaeee-3ded-43e8-a9d1-c28e6cbf73cdreponame:Biblioteca Digital de Teses e Dissertações do UFSMinstname:Universidade Federal de Santa Maria (UFSM)instacron:UFSMORIGINALTES_PPGFARMACOLOGIA_2017_BARBISAN_FERNANDA.pdfTES_PPGFARMACOLOGIA_2017_BARBISAN_FERNANDA.pdfTese de Doutoradoapplication/pdf4694878http://repositorio.ufsm.br/bitstream/1/13834/1/TES_PPGFARMACOLOGIA_2017_BARBISAN_FERNANDA.pdfd515c98bcdb189df30afb1befbd983c7MD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8804http://repositorio.ufsm.br/bitstream/1/13834/2/license_rdfc1efe8e24d7281448e873be30ea326ffMD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81956http://repositorio.ufsm.br/bitstream/1/13834/3/license.txt2f0571ecee68693bd5cd3f17c1e075dfMD53TEXTTES_PPGFARMACOLOGIA_2017_BARBISAN_FERNANDA.pdf.txtTES_PPGFARMACOLOGIA_2017_BARBISAN_FERNANDA.pdf.txtExtracted texttext/plain421107http://repositorio.ufsm.br/bitstream/1/13834/4/TES_PPGFARMACOLOGIA_2017_BARBISAN_FERNANDA.pdf.txtdb2b96efc17e8358451c1e37a2eec707MD54THUMBNAILTES_PPGFARMACOLOGIA_2017_BARBISAN_FERNANDA.pdf.jpgTES_PPGFARMACOLOGIA_2017_BARBISAN_FERNANDA.pdf.jpgIM Thumbnailimage/jpeg4346http://repositorio.ufsm.br/bitstream/1/13834/5/TES_PPGFARMACOLOGIA_2017_BARBISAN_FERNANDA.pdf.jpg838b68c75013822430f64ee013644c41MD551/138342022-04-28 08:27:45.7oai:repositorio.ufsm.br:1/13834TElDRU7Dh0EgREUgRElTVFJJQlVJw4fDg08gTsODTy1FWENMVVNJVkEKCkNvbSBhIGFwcmVzZW50YcOnw6NvIGRlc3RhIGxpY2Vuw6dhLCB2b2PDqiAobyBhdXRvciAoZXMpIG91IG8gdGl0dWxhciBkb3MgZGlyZWl0b3MgZGUgYXV0b3IpIGNvbmNlZGUgw6AgVW5pdmVyc2lkYWRlCkZlZGVyYWwgZGUgU2FudGEgTWFyaWEgKFVGU00pIG8gZGlyZWl0byBuw6NvLWV4Y2x1c2l2byBkZSByZXByb2R1emlyLCAgdHJhZHV6aXIgKGNvbmZvcm1lIGRlZmluaWRvIGFiYWl4byksIGUvb3UKZGlzdHJpYnVpciBhIHN1YSB0ZXNlIG91IGRpc3NlcnRhw6fDo28gKGluY2x1aW5kbyBvIHJlc3VtbykgcG9yIHRvZG8gbyBtdW5kbyBubyBmb3JtYXRvIGltcHJlc3NvIGUgZWxldHLDtG5pY28gZQplbSBxdWFscXVlciBtZWlvLCBpbmNsdWluZG8gb3MgZm9ybWF0b3Mgw6F1ZGlvIG91IHbDrWRlby4KClZvY8OqIGNvbmNvcmRhIHF1ZSBhIFVGU00gcG9kZSwgc2VtIGFsdGVyYXIgbyBjb250ZcO6ZG8sIHRyYW5zcG9yIGEgc3VhIHRlc2Ugb3UgZGlzc2VydGHDp8OjbwpwYXJhIHF1YWxxdWVyIG1laW8gb3UgZm9ybWF0byBwYXJhIGZpbnMgZGUgcHJlc2VydmHDp8Ojby4KClZvY8OqIHRhbWLDqW0gY29uY29yZGEgcXVlIGEgVUZTTSBwb2RlIG1hbnRlciBtYWlzIGRlIHVtYSBjw7NwaWEgYSBzdWEgdGVzZSBvdQpkaXNzZXJ0YcOnw6NvIHBhcmEgZmlucyBkZSBzZWd1cmFuw6dhLCBiYWNrLXVwIGUgcHJlc2VydmHDp8Ojby4KClZvY8OqIGRlY2xhcmEgcXVlIGEgc3VhIHRlc2Ugb3UgZGlzc2VydGHDp8OjbyDDqSBvcmlnaW5hbCBlIHF1ZSB2b2PDqiB0ZW0gbyBwb2RlciBkZSBjb25jZWRlciBvcyBkaXJlaXRvcyBjb250aWRvcwpuZXN0YSBsaWNlbsOnYS4gVm9jw6ogdGFtYsOpbSBkZWNsYXJhIHF1ZSBvIGRlcMOzc2l0byBkYSBzdWEgdGVzZSBvdSBkaXNzZXJ0YcOnw6NvIG7Do28sIHF1ZSBzZWphIGRlIHNldQpjb25oZWNpbWVudG8sIGluZnJpbmdlIGRpcmVpdG9zIGF1dG9yYWlzIGRlIG5pbmd1w6ltLgoKQ2FzbyBhIHN1YSB0ZXNlIG91IGRpc3NlcnRhw6fDo28gY29udGVuaGEgbWF0ZXJpYWwgcXVlIHZvY8OqIG7Do28gcG9zc3VpIGEgdGl0dWxhcmlkYWRlIGRvcyBkaXJlaXRvcyBhdXRvcmFpcywgdm9jw6oKZGVjbGFyYSBxdWUgb2J0ZXZlIGEgcGVybWlzc8OjbyBpcnJlc3RyaXRhIGRvIGRldGVudG9yIGRvcyBkaXJlaXRvcyBhdXRvcmFpcyBwYXJhIGNvbmNlZGVyIMOgIFVGU00Kb3MgZGlyZWl0b3MgYXByZXNlbnRhZG9zIG5lc3RhIGxpY2Vuw6dhLCBlIHF1ZSBlc3NlIG1hdGVyaWFsIGRlIHByb3ByaWVkYWRlIGRlIHRlcmNlaXJvcyBlc3TDoSBjbGFyYW1lbnRlCmlkZW50aWZpY2FkbyBlIHJlY29uaGVjaWRvIG5vIHRleHRvIG91IG5vIGNvbnRlw7pkbyBkYSB0ZXNlIG91IGRpc3NlcnRhw6fDo28gb3JhIGRlcG9zaXRhZGEuCgpDQVNPIEEgVEVTRSBPVSBESVNTRVJUQcOHw4NPIE9SQSBERVBPU0lUQURBIFRFTkhBIFNJRE8gUkVTVUxUQURPIERFIFVNIFBBVFJPQ8ONTklPIE9VCkFQT0lPIERFIFVNQSBBR8OKTkNJQSBERSBGT01FTlRPIE9VIE9VVFJPIE9SR0FOSVNNTyBRVUUgTsODTyBTRUpBIEEgVUZTTQosIFZPQ8OKIERFQ0xBUkEgUVVFIFJFU1BFSVRPVSBUT0RPUyBFIFFVQUlTUVVFUiBESVJFSVRPUyBERSBSRVZJU8ODTyBDT01PClRBTULDiU0gQVMgREVNQUlTIE9CUklHQcOHw5VFUyBFWElHSURBUyBQT1IgQ09OVFJBVE8gT1UgQUNPUkRPLgoKQSBVRlNNIHNlIGNvbXByb21ldGUgYSBpZGVudGlmaWNhciBjbGFyYW1lbnRlIG8gc2V1IG5vbWUgKHMpIG91IG8ocykgbm9tZShzKSBkbyhzKQpkZXRlbnRvcihlcykgZG9zIGRpcmVpdG9zIGF1dG9yYWlzIGRhIHRlc2Ugb3UgZGlzc2VydGHDp8OjbywgZSBuw6NvIGZhcsOhIHF1YWxxdWVyIGFsdGVyYcOnw6NvLCBhbMOpbSBkYXF1ZWxhcwpjb25jZWRpZGFzIHBvciBlc3RhIGxpY2Vuw6dhLgoKBiblioteca Digital de Teses e Dissertaçõeshttps://repositorio.ufsm.br/ONGhttps://repositorio.ufsm.br/oai/requestatendimento.sib@ufsm.br||tedebc@gmail.comopendoar:2022-04-28T11:27:45Biblioteca Digital de Teses e Dissertações do UFSM - Universidade Federal de Santa Maria (UFSM)false
dc.title.por.fl_str_mv A ação anti-inflamatória do lítio é influenciada por fatores genéticos, nutricionais e fármacos antidepressivos: estudos in vitro
dc.title.alternative.eng.fl_str_mv Antiinflammatory action of lithium is influenced by genetic, nutritional and antidepressant drugs: in vitro studies
title A ação anti-inflamatória do lítio é influenciada por fatores genéticos, nutricionais e fármacos antidepressivos: estudos in vitro
spellingShingle A ação anti-inflamatória do lítio é influenciada por fatores genéticos, nutricionais e fármacos antidepressivos: estudos in vitro
Barbisan, Fernanda
Polimorfismo genético
Imunosenescência
Xantinas
Catequinas
Inflamação
Estresse oxidativo
Depressão
Trantornos do espectro bipolar
Genetic polymorphism
Immunosenescence
Xanthines
Catechins
Inflammation
Oxidative stress
Depression
Bipolar disorders
CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA
title_short A ação anti-inflamatória do lítio é influenciada por fatores genéticos, nutricionais e fármacos antidepressivos: estudos in vitro
title_full A ação anti-inflamatória do lítio é influenciada por fatores genéticos, nutricionais e fármacos antidepressivos: estudos in vitro
title_fullStr A ação anti-inflamatória do lítio é influenciada por fatores genéticos, nutricionais e fármacos antidepressivos: estudos in vitro
title_full_unstemmed A ação anti-inflamatória do lítio é influenciada por fatores genéticos, nutricionais e fármacos antidepressivos: estudos in vitro
title_sort A ação anti-inflamatória do lítio é influenciada por fatores genéticos, nutricionais e fármacos antidepressivos: estudos in vitro
author Barbisan, Fernanda
author_facet Barbisan, Fernanda
author_role author
dc.contributor.advisor1.fl_str_mv Cruz, Ivana Beatrice Mânica da
dc.contributor.advisor1Lattes.fl_str_mv http://lattes.cnpq.br/3426369324110716
dc.contributor.referee1.fl_str_mv Pavanato, Maria Amália
dc.contributor.referee1Lattes.fl_str_mv http://lattes.cnpq.br/8701892865724171
dc.contributor.referee2.fl_str_mv Bica, Claudia Giuliano
dc.contributor.referee2Lattes.fl_str_mv http://lattes.cnpq.br/4488122519766245
dc.contributor.referee3.fl_str_mv Piccoli, Jacqueline da Costa Escobar
dc.contributor.referee3Lattes.fl_str_mv http://lattes.cnpq.br/5099227329574183
dc.contributor.referee4.fl_str_mv Premaor, Melissa Orlandin
dc.contributor.referee4Lattes.fl_str_mv http://lattes.cnpq.br/1919693261808995
dc.contributor.authorLattes.fl_str_mv http://lattes.cnpq.br/1428674947616182
dc.contributor.author.fl_str_mv Barbisan, Fernanda
contributor_str_mv Cruz, Ivana Beatrice Mânica da
Pavanato, Maria Amália
Bica, Claudia Giuliano
Piccoli, Jacqueline da Costa Escobar
Premaor, Melissa Orlandin
dc.subject.por.fl_str_mv Polimorfismo genético
Imunosenescência
Xantinas
Catequinas
Inflamação
Estresse oxidativo
Depressão
Trantornos do espectro bipolar
topic Polimorfismo genético
Imunosenescência
Xantinas
Catequinas
Inflamação
Estresse oxidativo
Depressão
Trantornos do espectro bipolar
Genetic polymorphism
Immunosenescence
Xanthines
Catechins
Inflammation
Oxidative stress
Depression
Bipolar disorders
CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA
dc.subject.eng.fl_str_mv Genetic polymorphism
Immunosenescence
Xanthines
Catechins
Inflammation
Oxidative stress
Depression
Bipolar disorders
dc.subject.cnpq.fl_str_mv CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA
description Population aging has increased the prevalence of chronic non-communicable diseases, including psychiatric disorders such as depression and bipolar spectrum disorders (BSDs). Evidence suggests that such disorders are associated with chronic processes of inflammation and oxidative stress. Lithium is one of the main drugs of the psychiatric clinic, and its main mechanism of action is anti-inflammatory by inhibition of the enzyme GSK-3β. However, about 40% of patients do not respond satisfactorily to Lithium therapy. And, this absense of response may involve genetic polymorphisms, or even drug-food interaction, or drug-drug, since lithium is often associated with antidepressants or antipsychotics. Therefore, in this work we emphasize the action of the polymorphism Val16Ala-SOD2 which causes imbalance between the levels of Superoxide and Hydrogen Peroxide and is involved with oxidative and inflammatory metabolism. Bioactive molecules such as xanthines and catechins present in foods, which have an anti-inflammatory and antioxidant effect, and therefore, they could also influence the pharmacological response to lithium and the interaction lithium-antidepressants, often used in TEBs. To evaluate in vitro the influence of genetic and nutritional factors and pharmacological interaction with antidepressants on the anti-inflammatory response of lithium. Three experimental designs were conducted. The first work evaluated the influence of the anti-inflammatory response to the Lithium of peripheral blood mononuclear cells (PBMCs) through two complementary studies. Initially, a study was conducted to confirm that such genetic variation could cause a differentiated inflammatory response evaluating the immunosenescence profile of these cells. Therefore, PBMCs were obtained from volunteers with different Val16Ala-SOD2 genotypes and were cultured for 15 cell passages (60 days) under standardized conditions. At each passage the PBMCs were activated with phytohemagglutinin (PHA), an antigen that triggers inflammatory response. At each passage the PBMCs were activated with phytohemagglutinin (PHA), an antigen that triggers inflammatory response. Each passage was started at a concentration of 1 x 105 cells. The rate of cell proliferation at each passage was determined via MTT spectrophotometric assay and, eventually, by cell cycle analysis by flow cytometry. Pro-inflammatory markers and oxidative markers were also analyzed. We performed a second study, which evaluated the influence of the Val16Ala-SOD2 polymorphism on the modulation of the GSK-3β enzyme by Lithium through the analysis of the gene expression via qRT-PCR and the levels of protein via immunoassay ELISA. We also performed analyzes with the RAW 264.7 macrophages commercial lineage in order to confirm the results obtained in PBMCs. Supplementation of cultures with paraquat to generate VV-like cells (with high levels of superoxide) was used to simulate the S-HP imbalance And porphyrin generating AA-like cells (with elevated PH levels). The second protocol of this work evaluated the potential isolated effect and a mixture of the xanthines and catechins in the anti-inflammatory response of lithium in macrophages RAW 264.7, through the analysis of oxidative and inflammatory markers. Finally, the third protocol evaluated the effect of the interaction between Lithium, Imipramine, Nortriptyline, Fluoxetine and Escitalopram also using RAW 264.7 macrophages as an experimental model. In this latter protocol, an inflammatory index (II) was created in order to aggregate the results obtained. In order to validate the II, a similar analysis was performed to the cells in vitro, in a database of 154 volunteers. This additional analysis allowed to evaluate the accuracy of the II and its potential similarity with inflammatory situations that occur in vivo. In in vitro studies the results were compared by analysis of variance (one-way or two-way, as appropriate) followed by post hoc Dunnet, Tukey or Bonferroni, according to the case. In the in vivo study, a Roc curve was performed to assess whether IF was representative of an actual inflammatory condition. A pattern of immunosenescence was observed in all cultures up to the 15th passage, when there was an interruption in the cell cycle in the G0 / G1 phase. However, prior to that, from the 10th cell passage, there was a state of inflammatory hyperactivation with high rates of cell proliferation and increased levels of proinflammatory cytokines and oxidative markers. Despite this general pattern, AA PBMCs showed greater intensity in the initial inflammatory response, whereas VV PBMCs tended to maintain the inflammatory response longer. Therefore, the set of these results corroborated the suggestion that the S-PH imbalance has a direct influence on the modulation of inflammation. The second study of the first protocol observed that the S-PH imbalance, both genetically determined by the Val16Ala-SOD2 polymorphism and pharmacologically induced influenced the anti-inflammatory response of the Lithium-modulating GSK-3β enzyme. Imbalance induced a more intense anti-inflammatory effect of lithium on AA or AA-like cells. In the second protocol, which evaluated the effect of nutritional factors on the anti-inflammatory action of lithium, especially the mixture of xanthines-catechins intensified the anti-inflammatory response of Lithium via decrease in the levels of pro-inflammatory cytokines, increase in IL-10 levels and decrease in oxidative markers. Finally, the last protocol investigated the influence of the interaction between lithium and antidepressants. The II was validated via analysis of the ROC curve showed that the II is an accurate index in relation to the inflammation with an area on the curve (AUC) of 0.803 (95% confidence interval of 0.715-0.890). Values of II > 2.0 relative to Reactive Protein C levels> 0.6 μg / mL had a sensitivity of 0.915 and specificity of 0.486. Interaction with antidepressants has shown that when Lithium is associated with Imipramine, or Nortriptyline or Fluoxetine, there is an intensification of the anti-inflammatory effect, with a decrease in the II, However, the association with Escitalopram induces pro-inflammatory effects, with an increase in IF indicating the proinflammatory effect of this interaction. In summary, despite the methodological limitations related to the in vitro studies, the set of results confirmed that Lithium has an important anti-inflammatory effect, but that this effect is not universal since it can be influenced by genetic, nutritional factors and even by interaction with antidepressant drugs. These results may be relevant in the psychiatric clinic.
publishDate 2017
dc.date.issued.fl_str_mv 2017-09-01
dc.date.accessioned.fl_str_mv 2018-07-18T14:05:44Z
dc.date.available.fl_str_mv 2018-07-18T14:05:44Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/doctoralThesis
format doctoralThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://repositorio.ufsm.br/handle/1/13834
url http://repositorio.ufsm.br/handle/1/13834
dc.language.iso.fl_str_mv por
language por
dc.relation.cnpq.fl_str_mv 201000000000
dc.relation.confidence.fl_str_mv 600
500
dc.relation.authority.fl_str_mv 0b5fcfe0-b017-4163-80e2-17c110fbcf01
62685ca4-85d0-44a7-80c0-58948463d7b9
ffd04c36-7494-45de-941b-897fca290f06
b013a08e-c6c6-4bbd-b823-a19a27e3c61c
1789009f-204a-4875-8758-7c9510ae4737
e4bbaeee-3ded-43e8-a9d1-c28e6cbf73cd
dc.rights.driver.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Universidade Federal de Santa Maria
Centro de Ciências da Saúde
dc.publisher.program.fl_str_mv Programa de Pós-Graduação em Farmacologia
dc.publisher.initials.fl_str_mv UFSM
dc.publisher.country.fl_str_mv Brasil
dc.publisher.department.fl_str_mv Farmacologia
publisher.none.fl_str_mv Universidade Federal de Santa Maria
Centro de Ciências da Saúde
dc.source.none.fl_str_mv reponame:Biblioteca Digital de Teses e Dissertações do UFSM
instname:Universidade Federal de Santa Maria (UFSM)
instacron:UFSM
instname_str Universidade Federal de Santa Maria (UFSM)
instacron_str UFSM
institution UFSM
reponame_str Biblioteca Digital de Teses e Dissertações do UFSM
collection Biblioteca Digital de Teses e Dissertações do UFSM
bitstream.url.fl_str_mv http://repositorio.ufsm.br/bitstream/1/13834/1/TES_PPGFARMACOLOGIA_2017_BARBISAN_FERNANDA.pdf
http://repositorio.ufsm.br/bitstream/1/13834/2/license_rdf
http://repositorio.ufsm.br/bitstream/1/13834/3/license.txt
http://repositorio.ufsm.br/bitstream/1/13834/4/TES_PPGFARMACOLOGIA_2017_BARBISAN_FERNANDA.pdf.txt
http://repositorio.ufsm.br/bitstream/1/13834/5/TES_PPGFARMACOLOGIA_2017_BARBISAN_FERNANDA.pdf.jpg
bitstream.checksum.fl_str_mv d515c98bcdb189df30afb1befbd983c7
c1efe8e24d7281448e873be30ea326ff
2f0571ecee68693bd5cd3f17c1e075df
db2b96efc17e8358451c1e37a2eec707
838b68c75013822430f64ee013644c41
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Biblioteca Digital de Teses e Dissertações do UFSM - Universidade Federal de Santa Maria (UFSM)
repository.mail.fl_str_mv atendimento.sib@ufsm.br||tedebc@gmail.com
_version_ 1793240118178349056